Prosecution Insights
Last updated: April 19, 2026
Application No. 18/080,165

HEMOSTATIC SPRAY

Final Rejection §102§103
Filed
Dec 13, 2022
Examiner
STIMPERT, PHILIP EARL
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Finemedix Co. Ltd.
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
3y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
537 granted / 857 resolved
-7.3% vs TC avg
Strong +49% interview lift
Without
With
+49.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
85 currently pending
Career history
942
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
50.1%
+10.1% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 857 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1 and 5-7 is/are rejected under 35 U.S.C. 103 as being unpatentable over US Pre-Grant Publication 2019/0232030 to Pic et al. (Pic hereinafter) in view of US Pre-Grant Publication 2004/0129270 to Fishman (Fishman). Regarding claim 1, Pic teaches a hemostatic sprayer (170, see Fig. 17) including a powder casing (190) having an accommodation space (200) therein storing hemostatic powder (54), an inlet port (192), an outlet port (196), a pressurized fluid supply source (which may be a receptacle in the form of a canister, see paragraph 22) separably connected to the inlet port, the supply port of the receptacle is opened due to a pressing by the powder casing (e.g. during assembly or replacement, see paragraph 63), the compressed gas is supplied with a preset pressure into the accommodation space and discharged through the outlet port with the hemostatic powder therein. Pic does not teach that the canister is opened as a result of pressing by the powder casing against the receptacle. Fishman teaches another medical gas system generally, and particularly teaches that a pressurized canister (210) may be opened by pressing an opening device (361, see Fig. 10C) into it. Fishman teaches that this provides a release mechanism for the gas (paragraph 234). One of ordinary skill in the art would have found it obvious before the effective filing date of the application to provide a canister and port as taught by Fishman to the canister of Pic in order to provide a release mechanism for gas which is otherwise stored in the receptacle. Regarding claim 5, Pic teaches a protective cap (202) that is indirectly and separably coupled to the inlet port (at 196) which blocks fluid from flowing into the inlet port, e.g. from the outlet (196). With respect to the order of assembly, this amounts to a product by process limitation which does not appear to confer any patentable distinction in structure and therefore does not distinguish over the Pic sprayer. Regarding claim 6, Pic teaches a connection member (180) which is coupled to the outlet port and is configured to be connected with a cannula of the proper size. Regarding claim 7, Pic teaches that a valve may be provided at the outlet port (see paragraph 27). Pic teaches that these valves may “manage the flow”, which is tantamount to locking and unlocking the valve and controlling the amount discharged. Claim(s) 2 is/are rejected under 35 U.S.C. 103 as being unpatentable over Pic in view of Fishman as applied to claim 1 above, and further in view of US Pre-Grant Publication 2005/0220721 to Kablik et al. (Kablik). Regarding claim 2, Pic teaches the limitations of claim 1 from which claim 2 depends, but does not teach the use of carbon dioxide gas. Kablik teaches another medical sprayer apparatus generally, and particularly teaches the use of a carbon dioxide canister as a propellant for medical powders (paragraph 41). Those of ordinary skill are aware of various advantages of the gas, such as wide commercial availability. One of ordinary skill in the art would have found it obvious before the effective filing date of the application to use carbon dioxide as taught by Kablik in order to use a commonly available material as a propellant. Regarding claim 8, Pic teaches the limitations of claim 1 from which claim 8 depends, and further teaches a cover casing (171) accommodating and covering the powder casing and an attached side of the receptacle of Kablik. Pic also teaches that various connections may be threaded (see e.g. paragraph 64). Those of skill in the art are well aware of the use of threaded engagements in forming sealed fluid connections within medical equipment. One of ordinary skill in the art would have found it obvious before the effective filing date of the application to couple the canister of Kablik with the casing (171) of Pic via a threaded engagement, which would constitute first and second coupling members as claimed. Regarding claim 9, Pic teaches a first guide hole (172) formed to provide a space in which an outside rotational force for pressing the powder casing is exerted without any interference while one portion of the powder casing (e.g. upper tip in Fig. 17) is exposed, and a second guide hole (also 64, see paragraph 64 stating that multiple such threads may be provided) formed such that the outlet port is exposed. Claim(s) 3 is/are rejected under 35 U.S.C. 103 as being unpatentable over in view of Fishman as applied to claim 1 above, and further in view of US Pre-Grant Publication 2016/0375202 to Goodman et al. (Goodman). Regarding claim 3, Pic teaches the limitations of claim 1 from which claim 3 depends, but does not teach the use of chitosan. Goodman teaches another hemostatic device, and particularly teaches the use of chitosan as a hemostat for controlling bleeding (see paragraph 3). One of ordinary skill in the art would have found it obvious before the effective filing date of the application to use chitosan as a hemostat in the sprayer of Pic in order to stop bleeding in a patient. Regarding claim 4, Pic teaches the limitations of claim 1 from which claim 3 depends, but does not teach the use of a membrane filter. Goodman teaches the use of a filter (50) in the form of a membrane for preventing powder from entering the pressure source (paragraph 54). One of ordinary skill in the art would have found it obvious before the effective filing date of the application to use a membrane filter as taught by Goodman in the sprayer of Pic in order to prevent powder from entering the pressure source. Response to Arguments Applicant’s arguments, see page 5, filed 1 October 2025, with respect to the rejection(s) of claim(s) under 35 U.S.C. 102 and 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Fishman as discussed above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PHILIP E STIMPERT whose telephone number is (571)270-1890. The examiner can normally be reached Monday-Friday, 8a-4p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at 571-270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PHILIP E STIMPERT/Primary Examiner, Art Unit 3783 13 January 2026
Read full office action

Prosecution Timeline

Dec 13, 2022
Application Filed
Aug 11, 2025
Non-Final Rejection — §102, §103
Oct 01, 2025
Response Filed
Jan 13, 2026
Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12577961
LOW-FLOW FLUID DELIVERY SYSTEM AND LOW-FLOW DEVICE THEREFOR
2y 5m to grant Granted Mar 17, 2026
Patent 12573932
LINEAR MOTOR AND LINEAR COMPRESSOR
2y 5m to grant Granted Mar 10, 2026
Patent 12560168
VARIABLE DISPLACEMENT PUMP
2y 5m to grant Granted Feb 24, 2026
Patent 12560173
MOTOR AND APPARATUS USING THE SAME
2y 5m to grant Granted Feb 24, 2026
Patent 12529366
MEMBRANE PUMP
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+49.3%)
3y 9m
Median Time to Grant
Moderate
PTA Risk
Based on 857 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month